Michael Huang

Dr. Huang has a history of successfully advancing small molecules, biologic agents and oligonucleotide therapies through all phases of development. His efforts have led to marketing authorizations for numerous therapeutics including Potiga®, Zevalin®, Uceris®, Ruconest®, and Austedo®. Dr. Huang is experienced in developing drug candidates across a broad array of indications including rare/orphan diseases. He has a history of building effective teams in biopharmaceutical companies and leading all functional aspects of drug development.

​

Prior to LifeMax, Dr. Huang served as Chief Medical Officer of Spruce Biosciences, where he advanced the company’s rare endocrine disease program from the initial IND through proof-of-concept and supported their successful financing and business-development activities. Prior to Spruce, Dr. Huang held roles of increasing responsibility including: VP of Clinical Development at Regulus Therapeutics where he led programs in hepatitis C and rare genetic kidney and cholestatic liver diseases; VP of Clinical Development at Auspex Pharmaceuticals (Huntington’s disease, tardive dyskinesia, and Tourette syndrome) until its acquisition by Teva; and Senior Medical Director at Santarus, Inc. (GI and rare diseases) until its acquisition by Salix.

​

Dr. Huang received his bachelor’s degree in molecular and cell biology from the University of California at Berkeley, his medical degree from the Chicago Medical School, and his post-graduate internship and residency training from the University of California at Irvine. Dr. Huang is the author or co-author of numerous peer-reviewed journal articles, abstracts, and scientific publications.